Tumor specific antibodies and t-cell receptors and methods of identifying the same
AssigneeBoard of Regents, The University of Texas System
InventorsGregory C. IPPOLITO, Jonathan R. MCDANIEL, William N. VOSS, George GEORGIOU
Life of this patent
Estimating the term…
Abstract
Methods are provided for identifying tumor-specific antibodies and/or T-cell receptors by paired mRNA sequencing from individual immune cells in sentinel lymph nodes and comparison of these sequences with corresponding mass spectroscopy data from a subject having a cancer. Novel tumor-specific antibodies (e.g., NY-ESO-1-binding antibodies) are also provided.
Claims84
A method for identifying cancer-specific antibody and/or T-cell receptor (TCR) sequences, comprising:
- a) obtaining the mRNA sequences from individual B-cells and/or individual T-cells obtained from a lymph node of a patient having cancer, wherein the B-cells and/or T-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired VH and VL and/or paired T-cell receptor polypeptides;
- and
- c) using the mRNA sequences to identify the amino acid sequences encoding the cancer-specific antibody and/or TCR polypeptides.
An isolated monoclonal antibody, wherein the antibody specifically binds to NY-ESO-1 and comprises:
- (I)
- (a) a first VH CDR identical to VH CDR1 of BC2-3G1 (GDSVSSNSAA;
- SEQ ID NO:
- 1), BC2-3G2 (GDSVSSNSAA;
- SEQ ID NO:
- 1), BC2-3G3 (GDSVSSNSAA;
- SEQ ID NO:
- 1), BC2-3G4 (GDSVSSNTAA;
- SEQ ID NO:
- 2), or BC2-3G0 (GDSVSSNSAA;
- SEQ ID NO:
- 1);
- (b) a second VH CDR identical to VH CDR2 of BC2-3G1 (TYYRSKWYN;
- SEQ ID NO:
- 3), BC2-3G2 (TYYRSKWYS;
- SEQ ID NO:
- 4), BC2-3G3 (TYYRSKWYS;
- SEQ ID NO:
- 4), BC2-3G4 (TYYRSRWYH;
- SEQ ID NO:
- 5), or BC2-3G0 (TYYRSKWYN;
- SEQ ID NO:
- 3);
- (c) a third VH CDR identical to VH CDR3 of BC2-3G1 (CARDLGIAAAGDFDYW;
- SEQ ID NO:
- 6), BC2-3G2 (CARDLGPAAAADFDYW;
- SEQ ID NO:
- 7), BC2-3G3 (CARDLGVTAAADFDFW;
- SEQ ID NO:
- 8), BC2-3G4 (CARDLGLAAAADFDFW;
- SEQ ID NO:
- 9), or BC2-3G0 (CARDLGIAAAGYFDYW;
- SEQ ID NO:
- 16);
- (d) a first VL CDR identical to VL CDR1 of BC2-3G1 (QGVSSY;
- SEQ ID NO:
- 10), BC2-3G2 (QSVSSY;
- SEQ ID NO:
- 11), BC2-3G3 (QSVSSY;
- SEQ ID NO:
- 11), BC2-3G4 (QSVSSY;
- SEQ ID NO:
- 11), or BC2-3G0 (QGVSSY;
- SEQ ID NO:
- 10);
- (e) a second VL CDR identical to VL CDR2 of BC2-3G1 (DAS;
- SEQ ID NO:
- 12), BC2-3G2 (DAS;
- SEQ ID NO:
- 12), BC2-3G3 (DAS;
- SEQ ID NO:
- 12), BC2-3G4 (DAS;
- SEQ ID NO:
- 12), or BC2-3G0 (DAS;
- SEQ ID NO:
- 12);
- and
- (f) a third VL CDR identical to VL CDR3 of BC2-3G1 (CHQGSNWPTF;
- SEQ ID NO:
- 13), BC2-3G2 (CHQHFNWPTF;
- SEQ ID NO:
- 14), BC2-3G3 (CHQHFNWPTF;
- SEQ ID NO:
- 14), BC2-3G4 (CHQHRSWPTF;
- SEQ ID NO:
- 15) or BC2-3G0 (CQQRSNWLTF;
- SEQ ID NO:
- 17);
- or
- (II)
- (a) a first VH CDR identical to VH CDR1 of BC2-4G0 (GGSISSY;
- SEQ ID NO:
- 18), BC2-4G1 (GGSITNY;
- SEQ ID NO:
- 19), or BC2-4G2 (GGSISNY;
- SEQ ID NO:
- 20);
- (b) a second VH CDR identical to VH CDR2 of BC2-4G0 (IYYSGST;
- SEQ ID NO:
- 21), BC2-4G1 (IYYSGNT;
- SEQ ID NO:
- 22), or BC2-4G2 (IYYNGNT;
- SEQ ID NO:
- 23);
- (c) a third VH CDR identical to VH CDR3 of BC2-4G0 (CARHGLGWDLYYFDYW;
- SEQ ID NO:
- 24), BC2-4G1 (CARHGLGWDLYYFDYW;
- SEQ ID NO:
- 24), or BC2-4G2 (CARHGSGWDLYYFDYW;
- SEQ ID NO:
- 25);
- (d) a first VL CDR identical to VL CDR1 of BC2-4G0 (SSNIGAGYD;
- SEQ ID NO:
- 26), BC2-4G1 (SSNIGAGYD;
- SEQ ID NO:
- 26), or BC2-4G2 (SLNIGAGYD;
- SEQ ID NO:
- 27);
- (e) a second VL CDR identical to VL CDR2 of BC2-4G0 (GNS;
- SEQ ID NO:
- 28), BC2-4G1 (GNT;
- SEQ ID NO:
- 29), or BC2-4G2 (SNN;
- SEQ ID NO:
- 30);
- and
- (f) a third VL CDR identical to VL CDR3 of BC2-4G0 (CQSYDSSLSGYVF;
- SEQ ID NO:
- 31), BC2-4G1 (CQSYDSSLIGYVF;
- SEQ ID NO:
- 32), or BC2-4G2 (CQSYDASLKGYVF;
- SEQ ID NO:
- 33);
- or
- (III)
- (a) a first VH CDR identical to VH CDR1 of BC2-5G1 (GGTFSSYA;
- SEQ ID NO:
- 34), or BC2-5G2 (GGTFSSYA;
- SEQ ID NO:
- 34);
- (b) a second VH CDR identical to VH CDR2 of BC2-5G1 (IIPILGIA;
- SEQ ID NO:
- 35), or BC2-5G2 (IIPILGVT;
- SEQ ID NO:
- 36);
- (c) a third VH CDR identical to VH CDR3 of BC2-5G1 (CASVTSRYW;
- SEQ ID NO:
- 44), or BC2-5G2 (CASVTSGYW;
- SEQ ID NO:
- 37);
- (d) a first VL CDR identical to VL CDR1 of BC2-5G1 (QSVSSSS;
- SEQ ID NO:
- 38), or BC2-5G2 (QSISSSY;
- SEQ ID NO:
- 39);
- (e) a second VL CDR identical to VL CDR2 of BC2-5G1 (GAS;
- SEQ ID NO:
- 40), or BC2-5G2 (SAS;
- SEQ ID NO:
- 41);
- and
- (f) a third VL CDR identical to VL CDR3 of BC2-5G1 (CQQHGISPPFMYTF;
- SEQ ID NO:
- 42), or BC2-5G2 (CQHYGSSPAFMYTF;
- SEQ ID NO:
- 43).
A mosaic plot of data showing quantified individual tumor specific B-cells and/or individual tumor specific T-cells encoding each unique antibody and/or TCR polypeptide.
A computer readable media comprising a mosaic plot of data showing quantified individual tumor specific B-cells and/or individual tumor specific T-cells encoding each unique antibody and/or TCR polypeptide.
A chimeric antigen receptor (CAR) protein, wherein the CAR protein binds NY-ESO-1 and comprises:
- (I)
- (a) a first VH CDR identical to VH CDR1 of BC2-3G1 (GDSVSSNSAA;
- SEQ ID NO:
- 1), BC2-3G2 (GDSVSSNSAA;
- SEQ ID NO:
- 1), BC2-3G3 (GDSVSSNSAA;
- SEQ ID NO:
- 1), BC2-3G4 (GDSVSSNTAA;
- SEQ ID NO:
- 2), or BC2-3G0 (GDSVSSNSAA;
- SEQ ID NO:
- 1);
- (b) a second VH CDR identical to VH CDR2 of BC2-3G1 (TYYRSKWYN;
- SEQ ID NO:
- 3), BC2-3G2 (TYYRSKWYS;
- SEQ ID NO:
- 4), BC2-3G3 (TYYRSKWYS;
- SEQ ID NO:
- 4), BC2-3G4 (TYYRSRWYH;
- SEQ ID NO:
- 5), or BC2-3G0 (TYYRSKWYN;
- SEQ ID NO:
- 3);
- (c) a third VH CDR identical to VH CDR3 of BC2-3G1 (CARDLGIAAAGDFDYW;
- SEQ ID NO:
- 6), BC2-3G2 (CARDLGPAAAADFDYW;
- SEQ ID NO:
- 7), BC2-3G3 (CARDLGVTAAADFDFW;
- SEQ ID NO:
- 8), BC2-3G4 (CARDLGLAAAADFDFW;
- SEQ ID NO:
- 9), or BC2-3G0 (CARDLGIAAAGYFDYW;
- SEQ ID NO:
- 16);
- (d) a first VL CDR identical to VL CDR1 of BC2-3G1 (QGVSSY;
- SEQ ID NO:
- 10), BC2-3G2 (QSVSSY;
- SEQ ID NO:
- 11), BC2-3G3 (QSVSSY;
- SEQ ID NO:
- 11), BC2-3G4 (QSVSSY;
- SEQ ID NO:
- 11), or BC2-3G0 (QGVSSY;
- SEQ ID NO:
- 10);
- (e) a second VL CDR identical to VL CDR2 of BC2-3G1 (DAS;
- SEQ ID NO:
- 12), BC2-3G2 (DAS;
- SEQ ID NO:
- 12), BC2-3G3 (DAS;
- SEQ ID NO:
- 12), BC2-3G4 (DAS;
- SEQ ID NO:
- 12), or BC2-3G0 (DAS;
- SEQ ID NO:
- 12);
- and
- (f) a third VL CDR identical to VL CDR3 of BC2-3G1 (CHQGSNWPTF;
- SEQ ID NO:
- 13), BC2-3G2 (CHQHFNWPTF;
- SEQ ID NO:
- 14), BC2-3G3 (CHQHFNWPTF;
- SEQ ID NO:
- 14), BC2-3G4 (CHQHRSWPTF;
- SEQ ID NO:
- 15) or BC2-3G0 (CQQRSNWLTF;
- SEQ ID NO:
- 17);
- or
- (II)
- (a) a first VH CDR identical to VH CDR1 of BC2-4G0 (GGSISSY;
- SEQ ID NO:
- 18), BC2-4G1 (GGSITNY;
- SEQ ID NO:
- 19), or BC2-4G2 (GGSISNY;
- SEQ ID NO:
- 20);
- (b) a second VH CDR identical to VH CDR2 of BC2-4G0 (IYYSGST;
- SEQ ID NO:
- 21), BC2-4G1 (IYYSGNT;
- SEQ ID NO:
- 22), or BC2-4G2 (IYYNGNT;
- SEQ ID NO:
- 23);
- (c) a third VH CDR identical to VH CDR3 of BC2-4G0 (CARHGLGWDLYYFDYW;
- SEQ ID NO:
- 24), BC2-4G1 (CARHGLGWDLYYFDYW;
- SEQ ID NO:
- 24), or BC2-4G2 (CARHGSGWDLYYFDYW;
- SEQ ID NO:
- 25);
- (d) a first VL CDR identical to VL CDR1 of BC2-4G0 (SSNIGAGYD;
- SEQ ID NO:
- 26), BC2-4G1 (SSNIGAGYD;
- SEQ ID NO:
- 26), or BC2-4G2 (SLNIGAGYD;
- SEQ ID NO:
- 27);
- (e) a second VL CDR identical to VL CDR2 of BC2-4G0 (GNS;
- SEQ ID NO:
- 28), BC2-4G1 (GNT;
- SEQ ID NO:
- 29), or BC2-4G2 (SNN;
- SEQ ID NO:
- 30);
- and
- (f) a third VL CDR identical to VL CDR3 of BC2-4G0 (CQSYDSSLSGYVF;
- SEQ ID NO:
- 31), BC2-4G1 (CQSYDSSLIGYVF;
- SEQ ID NO:
- 32), or BC2-4G2 (CQSYDASLKGYVF;
- SEQ ID NO:
- 33);
- or
- (III)
- (a) a first VH CDR identical to VH CDR1 of BC2-5G1 (GGTFSSYA;
- SEQ ID NO:
- 34), or BC2-5G2 (GGTFSSYA;
- SEQ ID NO:
- 34);
- (b) a second VH CDR identical to VH CDR2 of BC2-5G1 (IIPILGIA;
- SEQ ID NO:
- 35), or BC2-5G2 (IIPILGVT;
- SEQ ID NO:
- 36);
- (c) a third VH CDR identical to VH CDR3 of BC2-5G1 (CASVTSRYW;
- SEQ ID NO:
- 44), or BC2-5G2 (CASVTSGYW;
- SEQ ID NO:
- 37);
- (d) a first VL CDR identical to VL CDR1 of BC2-5G1 (QSVSSSS;
- SEQ ID NO:
- 38), or BC2-5G2 (QSISSSY;
- SEQ ID NO:
- 39);
- (e) a second VL CDR identical to VL CDR2 of BC2-5G1 (GAS;
- SEQ ID NO:
- 40), or BC2-5G2 (SAS;
- SEQ ID NO:
- 41);
- and
- (f) a third VL CDR identical to VL CDR3 of BC2-5G1 (CQQHGISPPFMYTF;
- SEQ ID NO:
- 42), or BC2-5G2 (CQHYGSSPAFMYTF;
- SEQ ID NO:
- 43).
Dependencies are inferred from the claim text.